Naturewise Biotech & Medicals Corporation(TW:4732)
NT$15.20+0.30 (+2.01%)
TW:4732
Naturewise Biotech & Medicals Corporation financials statements
NT$15.20
At close:+0.30 (+2.01%)
Naturewise Biotech & Medicals Corporation (4732) Ratios
Naturewise Biotech & Medicals Corporation Ratios
TW:4732's free cash flow for Q2 2026 was NT$-81.79M. For the 2026 fiscal year, TW:4732's free cash flow was increased by NT$0.00 and operating cash flow was NT$-81.79M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.66 | 15.28 | 11.55 | 14.52 | 9.12 |
| Quick Ratio | 9.33 | 13.61 | 10.03 | 13.13 | 8.31 |
| Cash Ratio | 1.63 | 6.34 | 2.07 | 2.31 | 2.28 |
| Solvency Ratio | -1.49 | 0.21 | 0.32 | 0.80 | 0.52 |
| Operating Cash Flow Ratio | -1.88 | -0.06 | 1.15 | 0.41 | 0.43 |
| Short-Term Operating Cash Flow Coverage | -18.76 | -7.64 | 21.44 | 7.64 | 4.91 |
| Net Current Asset Value | NT$ 565.60M | NT$ 713.63M | NT$ 562.12M | NT$ 571.17M | NT$ 543.55M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.00 | 0.02 | 0.01 | 0.02 |
| Debt-to-Equity Ratio | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 |
| Debt-to-Capital Ratio | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.14 | 1.13 | 1.10 | 1.08 | 1.13 |
| Debt Service Coverage Ratio | -18.56 | 16.18 | 6.97 | 16.02 | 6.46 |
| Interest Coverage Ratio | -1526.69 | -121.58 | 66.04 | 658.67 | 843.03 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.26 | 0.08 | 0.22 | 0.10 | 0.26 |
| Net Debt to EBITDA | 0.89 | -42.40 | -5.00 | -2.52 | -3.74 |
| Profitability Margins | |||||
| Gross Profit Margin | 48.48% | 53.58% | 54.56% | 52.05% | 54.00% |
| EBIT Margin | -60.46% | -1.58% | 6.23% | 11.53% | 10.80% |
| EBITDA Margin | -54.20% | 3.32% | 12.73% | 16.31% | 15.32% |
| Operating Profit Margin | -60.46% | -5.37% | 2.14% | 11.53% | 10.80% |
| Pretax Profit Margin | -57.44% | -1.63% | 6.20% | 13.13% | 12.27% |
| Net Profit Margin | -67.00% | 0.40% | 6.32% | 13.13% | 12.33% |
| Continuous Operations Profit Margin | -67.00% | -1.60% | 6.32% | 13.13% | 12.33% |
| Net Income Per EBT | 116.64% | -24.59% | 101.98% | 100.00% | 100.55% |
| EBT Per EBIT | 95.01% | 30.31% | 288.99% | 113.96% | 113.58% |
| Return on Assets (ROA) | -16.61% | 0.11% | 1.45% | 4.33% | 4.37% |
| Return on Equity (ROE) | -18.97% | 0.12% | 1.60% | 4.68% | 4.93% |
| Return on Capital Employed (ROCE) | -16.36% | -1.52% | 0.53% | 4.05% | 4.24% |
| Return on Invested Capital (ROIC) | -16.22% | -1.49% | 0.53% | 4.02% | 4.18% |
| Return on Tangible Assets | -17.25% | 0.11% | 1.53% | 4.62% | 4.69% |
| Earnings Yield | -11.69% | 0.07% | 0.74% | 1.73% | 1.21% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.80 | 3.95 | 2.90 | 3.55 | 3.82 |
| Payables Turnover | 6.09 | 8.26 | 3.62 | 16.84 | 6.73 |
| Inventory Turnover | 1.15 | 1.23 | 0.88 | 1.84 | 2.06 |
| Fixed Asset Turnover | 14.16 | 56.62 | 18.58 | 63.02 | 30.25 |
| Asset Turnover | 0.25 | 0.27 | 0.23 | 0.33 | 0.35 |
| Working Capital Turnover Ratio | 0.27 | 0.35 | 0.28 | 0.40 | 0.46 |
| Cash Conversion Cycle | 388.79 | 343.86 | 438.87 | 279.41 | 218.71 |
| Days of Sales Outstanding | 130.25 | 92.31 | 125.74 | 102.75 | 95.67 |
| Days of Inventory Outstanding | 318.46 | 295.74 | 413.84 | 198.34 | 177.26 |
| Days of Payables Outstanding | 59.93 | 44.19 | 100.72 | 21.67 | 54.22 |
| Operating Cycle | 448.72 | 388.05 | 539.59 | 301.08 | 272.93 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.31 | -0.06 | 1.25 | 0.35 | 0.59 |
| Free Cash Flow Per Share | -2.32 | -0.06 | 1.23 | 0.35 | 0.59 |
| Dividend Paid and CapEx Coverage Ratio | -134.21 | -0.28 | 2.46 | 1.17 | 6.02 |
| Capital Expenditure Coverage Ratio | -134.21 | -19.55 | 98.11 | 115.01 | 165.13 |
| Operating Cash Flow Coverage Ratio | -8.86 | -0.74 | 5.82 | 3.50 | 2.31 |
| Operating Cash Flow to Sales Ratio | -0.64 | -0.01 | 0.39 | 0.08 | 0.12 |
| Free Cash Flow Yield | -11.20% | -0.24% | 4.49% | 1.00% | 1.14% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.98 | 1388.89 | 137.25 | 57.79 | 82.90 |
| Price-to-Sales (P/S) Ratio | 5.73 | 5.55 | 8.55 | 7.60 | 10.15 |
| Price-to-Book (P/B) Ratio | 1.62 | 1.68 | 2.16 | 2.71 | 4.06 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -8.93 | -424.09 | 22.25 | 100.26 | 87.79 |
| Price-to-Operating Cash Flow Ratio | -9.00 | -445.79 | 22.02 | 99.39 | 87.26 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -15.26 | -2.04 | -35.83 | -1.56 |
| Enterprise Value Multiple | -9.69 | 124.69 | 62.18 | 44.08 | 62.53 |
| Enterprise Value | 928.17M | 929.80M | 1.27B | 1.64B | 2.39B |
| EV to EBITDA | -9.69 | 124.69 | 62.18 | 44.08 | 62.53 |
| EV to Sales | 5.25 | 4.14 | 7.92 | 7.19 | 9.58 |
| EV to Free Cash Flow | -8.18 | -316.47 | 20.60 | 94.84 | 82.84 |
| EV to Operating Cash Flow | -8.24 | -332.66 | 20.39 | 94.01 | 82.34 |
| Tangible Book Value Per Share | 12.58 | 15.09 | 11.95 | 12.15 | 11.69 |
| Shareholders’ Equity Per Share | 12.79 | 14.87 | 12.70 | 13.02 | 12.66 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.17 | 0.02 | -0.02 | 0.00 | -0.01 |
| Revenue Per Share | 3.62 | 4.50 | 3.21 | 4.64 | 5.06 |
| Net Income Per Share | -2.43 | 0.02 | 0.20 | 0.61 | 0.62 |
| Tax Burden | 1.17 | -0.25 | 1.02 | 1.00 | 1.01 |
| Interest Burden | 0.95 | 1.03 | 0.99 | 1.14 | 1.14 |
| Research & Development to Revenue | 0.75 | 0.32 | 0.19 | 0.22 | 0.28 |
| SG&A to Revenue | 0.28 | 0.27 | 0.34 | 0.24 | 0.20 |
| Stock-Based Compensation to Revenue | 0.00 | 0.03 | 0.04 | 0.01 | 0.00 |
| Income Quality | 1.22 | 0.77 | 6.15 | 0.58 | 0.94 |
Currency in TWD
